Two medical cannabis companies moved to intervene in litigation over cannabis rescheduling, arguing that court rulings blocking the policy change would cause direct financial and regulatory harm. The firms told a federal court they will “suffer direct economic, regulatory and operational harm” if lawsuits succeed in undoing the Trump administration’s rescheduling action.
Federal developments
The intervention came amid broader federal activity. Four House members—Reps. Morgan Luttrell (R-TX), Lou Correa (D-CA), Jack Bergman (R-MI) and Michael McCaul (R-TX)—filed the IBOGAINE Act, a bill that would codify President Trump’s executive order on psychedelics and make statutory changes tied to that order. The bill text seeks to move specific psychedelics policy decisions into statute, shifting some regulatory authority and establishing new legal frameworks for certain substances.
Separately, attorneys Brett Schuman and Adam Horowitz of Goodwin Procter LLP argued in an op-ed that the Drug Enforcement Administration’s decision to invite only opponents of rescheduling to an administrative hearing could reflect a legal strategy. They wrote that the DEA may be structuring the record to withstand likely judicial review if an administrative law judge recommends moving cannabis from Schedule I to Schedule III.
Representative Brian Mast (R-FL) published commentary on marijuana banking policy, reiterating congressional attention to how federal financial rules should treat cannabis businesses.
State policy updates
Delaware: Lawmakers overrode Gov. Matt Meyer’s veto of a bill that limits county ability to impose restrictive zoning on marijuana businesses. The override restores a state-level restriction on local zoning measures that advocates say were blocking dispensary and cultivation licenses in some counties.
Georgia: A new medical cannabis law took effect that expands the list of qualifying medical conditions, authorizes vaping of whole flower for registered patients, and changes THC potency limits for medical products. Regulators are now updating licensing and compliance guidance to reflect the statutory changes.
Nebraska: Gov. Jim Pillen (R) signed medical cannabis regulations one day after the state attorney general approved them, finalizing rules that cover licensing, testing and product standards.
Hawaii: State regulators face a federal lawsuit challenging newly enforced restrictions on hemp products. The complaint alleges the rules exceed federal and state law and seeks to halt enforcement actions against retailers and manufacturers.
Other state-level items
– Pennsylvania: House Minority Leader reported that negotiations to include adult-use legalization in the state budget have slowed in recent days. – Oregon: Regulators announced a combined oversight structure for medical cannabis and psilocybin services, consolidating inspections and licensing teams to use shared procedures and compliance standards. – Rhode Island: State Police are accused in court filings of relying on faulty or unvalidated evidence in a marijuana-related investigation; civil and criminal defense attorneys have pressed for review of the methods used. – Michigan: The state published a report listing disciplinary actions taken against regulated marijuana businesses, including license suspensions and fines tied to packaging, safety and reporting violations. – California: Regulators issued multiple bulletin updates on product testing, supply-chain reporting and enforcement priorities. – Oklahoma: The medical marijuana regulatory agency launched a public website detailing its new quality assurance laboratory, including testing protocols and turnaround targets.
Local and international items
A New Jersey judge issued a temporary restraining order preventing Haledon officials from blocking a marijuana dispensary from opening while a lawsuit over municipal approvals proceeds.
The United Nations Office on Drugs and Crime released its annual World Drug Report, which includes sections critical of some countries’ cannabis reform moves and urges caution in policy shifts. An Isle of Man lawmaker has publicly asked government officials for precise revenue figures from the island’s medical cannabis program, seeking quarterly sales and tax data.
Science, business and culture
Science: A laboratory study reported that two minor cannabinoids, cannabigerol (CBG) and cannabichromene (CBC), induced cell death and apoptosis in lung cancer cell lines. Separately, a veterinary case report described use of combined THC-rich and CBD-rich cannabis oils as an adjunct to multimodal palliative care in horses with chronic, treatment-resistant conditions; authors called for controlled studies to evaluate safety and dosing.
Business: Point-of-sale software company Flowhub launched a feature that lets clients connect third-party artificial intelligence services to its platform for inventory analysis and sales forecasting. The company said the tool aims to reduce manual reporting time and speed compliance checks.
Culture: Actor and cannabis entrepreneur Seth Rogen recounted smoking marijuana with Paul McCartney and actor Paul Rudd in a recent interview, noting the interaction as a light-hearted moment that drew media attention.
What to watch next
Key litigation will determine whether federal rescheduling moves remain in place. If courts block the administration’s action, cannabis businesses predict immediate financial impacts: lost access to certain federal banking accommodations, altered tax treatments, and changes to interstate commerce plans tied to Schedule III classification. State-level regulatory changes—particularly Georgia’s new medical rules and Delaware’s zoning override—will affect licensing timelines and market access in the coming months.
For stakeholders: monitor filings in the intervention motion, the administrative hearing record at the DEA, and text of any final regulations from state agencies to track specific compliance deadlines and financial consequences.
